RKLB March 6th Options Begin Trading

Rocket Lab (RKLB) option flow shows a sell-to-open put at the $82 strike with a bid of $8.40, implying a net cost basis of $73.60 if assigned (current stock $84.86), ~3% OTM and a 61% probability to expire worthless, representing a 10.24% return on cash (86.95% annualized). On the call side, a covered call at the $86 strike with an $8.85 bid would yield a 11.77% return if called at the March 6 expiration (1% OTM) with a 45% chance to expire worthless and a 10.43% YieldBoost (88.52% annualized); implied volatilities are ~101% (put) and 91% (call) versus 12-month trailing volatility of 83%.

Analysis

Market structure: The option chain shows sellers can collect large premia (put $8.40 at $82, call $8.85 at $86) because IV is rich (puts 101%, calls 91% vs trailing vol 83%), so short-premium retail/income players and market-makers win short-term carry while directional upside holders risk being capped or assigned. Order flow that favors put selling will create latent buy-side pressure if many contracts are assigned, tightening float temporarily; conversely a negative operational shock (launch failure, dilutive raise) would flip that dynamic quickly.

Risk assessment: Tail risks are operational (failed/ delayed launches), dilution (equity raises if cash burn continues) and event-driven volatility — any one can collapse IV from ~100% to <50% and gap stock >>10% overnight. Immediate horizon is to March 6 expiry (days/weeks) where time decay dominates; over months quarters the company’s cash runway, contract cadence and launch manifest drive realized vol and fundamentals.

Trade implications: For tactical income, selling the Mar 6 $82 put or buying shares and selling the Mar 6 $86 call are high-yield plays but carry gap/assignment risk; prefer defined-risk put-credit spreads (sell $82, buy $72) or covered-call with stop-loss at $70 to cap downside. Size trades small (1–3% net equity) and use IV/price triggers: enter if IV> trailing vol by >15% and exit if IV compresses >20% or stock gaps >8% adverse.

Contrarian angles: Consensus celebrates the headline yields but underestimates operational tail risk — IV likely reflects real catalyst concentration (launches/contracts) so premium may be fair, not free. Historical parallels: space/launch names spike IV pre-launch and collapse on success; if you expect a successful manifest in 4–8 weeks, selling premium is underdone; if you fear a failed launch or cash raise, current pricing underestimates downside and you should buy protection.

Key Decisions for Investors

• Sell-to-open 1x RKLB Mar 6 $82 put (collect ~$8.40) size = 1%–2% portfolio notional; only if you are willing to own 100 shares at $73.60 basis. Predefine exit: close if RKLB < $70 or IV falls >20% from trade entry.
• If you want defined risk, execute a put-credit spread: sell RKLB Mar 6 $82 put and buy Mar 6 $72 put to cap max loss (~$8 per share worst case). Keep sizing to 1% notional and close 50% of position on a favorable 50% of max profit.
• Buy 100 RKLB shares and sell Mar 6 $86 call (covered call) to collect ~$8.85 (net basis ~$76.01); target holding period = up to expiry (days–weeks). Roll or close if price >$90 pre-expiry or if RKLB < $70 to limit downside.
• Avoid unilateral long equity exposure >3% of portfolio ahead of next 90 days unless company releases firm launch manifest or contract wins; alternatively implement a relative pair: long RKLB covered-call (as above) and short 0.4–0.6x notional of space/defense ETF (e.g., ARKX) to hedge beta and isolate idiosyncratic outcome.